Arcutis Biotherapeutics, Inc.
ARQT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787306
In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Arcutis Biotherapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 188
- +3 vs. Q2 2024
- Shares held
- 128.6M
- +10.8M (+9.1%) vs. Q2 2024
- Total value
- $1.20B
- +$101.8M (+9.3%) vs. Q2 2024
- New holders
- 34
- 72 more added
- Sold out
- 31
- 48 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARQT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 272 | $3.45B |
| Q1 2026 | 270 | $3.12B |
| Q4 2025 | 283 | $3.75B |
| Q3 2025 | 239 | $2.37B |
| Q2 2025 | 230 | $1.78B |
| Q1 2025 | 241 | $1.97B |
| Q4 2024 | 208 | $1.79B |
| Q3 2024 | 188 | $1.20B |
| Q2 2024 | 186 | $1.18B |
| Q1 2024 | 168 | $1.24B |
| Q4 2023 | 133 | $327.1M |
| Q3 2023 | 134 | $356.7M |
| Q2 2023 | 136 | $684.0M |
| Q1 2023 | 144 | $787.6M |
| Q4 2022 | 141 | $979.6M |
| Q3 2022 | 139 | $1.13B |
| Q2 2022 | 115 | $1.05B |
| Q1 2022 | 106 | $929.8M |
| Q4 2021 | 93 | $961.8M |
| Q3 2021 | 103 | $1.09B |
| Q2 2021 | 102 | $1.24B |
| Q1 2021 | 94 | $1.35B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Arcutis Biotherapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −52,244−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −45,019−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −37,730−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −27,899−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −26,500−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −21,631−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −18,555−100.0% | Sold out |
| Entropy Technologies, LP | 0 | $0 | 0.00% | −11,772−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Castleview Partners, LLC | 0 | $0 | 0.00% | −8,113−100.0% | Sold out |
| Allianz SE | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Coppell Advisory Solutions LLC | 0 | $0 | 0.00% | −2,319−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −1,555−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,476−100.0% | Sold out |
| Macroview Investment Management LLC | 0 | $0 | 0.00% | −875−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −606−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −539−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −398−100.0% | Sold out |
| Mather Group, LLC. | 0 | $0 | 0.00% | −190−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |